相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Drug conjugate-based anticancer therapy-Current status and perspectives
Yuqi Yang et al.
CANCER LETTERS (2023)
Development of an LC-MS/MS Method for ARV-110, a PROTAC Molecule, and Applications to Pharmacokinetic Studies
Thi-Thao-Linh Nguyen et al.
MOLECULES (2022)
Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer
Arif Hussain et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2021)
Investigating the performance of a novel pH and cathepsin B sensitive, stimulus-responsive nanoparticle for optimised sonodynamic therapy in prostate cancer
Marym Mohammad Hadi et al.
JOURNAL OF CONTROLLED RELEASE (2021)
Disitamab Vedotin: First Approval
Emma D. Deeks
DRUGS (2021)
An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
Juliana T. W. Tong et al.
MOLECULES (2021)
Extracellular HSP90 Machineries Build Tumor Microenvironment and Boost Cancer Progression
Pietro Poggio et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Novel Strategies for Treating Castration-Resistant Prostate Cancer
David Ka-Wai Leung et al.
BIOMEDICINES (2021)
The Chemistry Behind ADCs
Vesela Kostova et al.
PHARMACEUTICALS (2021)
Advancements in folate receptor targeting for anti-cancer therapy: A small molecule-drug conjugate approach
Abhilash Rana et al.
BIOORGANIC CHEMISTRY (2021)
Near Infrared Photoimmunotherapy; A Review of Targets for Cancer Therapy
Takuya Kato et al.
CANCERS (2021)
Design, Synthesis, and Biological Evaluation of HSP90 Inhibitor-SN38 Conjugates for Targeted Drug Accumulation
Shulei Zhu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease
Rebecca Smith et al.
SCIENTIFIC REPORTS (2020)
A tumor-targeted Ganetespib-zinc phthalocyanine conjugate for synergistic chemo-photodynamic therapy
Liangfeng Huang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Tumor target amplification: Implications for nano drug delivery systems
Khaled Seidi et al.
JOURNAL OF CONTROLLED RELEASE (2018)
A Fluorescent Hsp90 Probe Demonstrates the Unique Association between Extracellular Hsp90 and Malignancy in Vivo
Lauren B. Crowe et al.
ACS CHEMICAL BIOLOGY (2017)
TGF-β Conveys Undesirable Side Effects of Androgen Depletion
Natasha Kyprianou
ENDOCRINOLOGY (2016)
Antibody-drug conjugates for cancer therapy
Anish Thomas et al.
LANCET ONCOLOGY (2016)
Cotargeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer
Long Chen et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms
Margaret M. Centenera et al.
ENDOCRINE-RELATED CANCER (2015)
HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors
David A. Proia et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Ganetespib: research and clinical development
Komal Jhaveri et al.
ONCOTARGETS AND THERAPY (2015)
Heat shock protein 90 targets a chaperoned peptide to the static early endosome for efficient cross-presentation by human dendritic cells
Tsutomu Tanaka et al.
CANCER SCIENCE (2015)
Muscle and bone effects of androgen deprivation therapy: current and emerging therapies
Ada S. Cheung et al.
ENDOCRINE-RELATED CANCER (2014)
Hsp90: Still a viable target in prostate cancer
Margaret M. Centenera et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2013)
Optical and Radioiodinated Tethered Hsp90 Inhibitors Reveal Selective Internalization of Ectopic Hsp90 in Malignant Breast Tumor Cells
Jared J. Barrott et al.
CHEMISTRY & BIOLOGY (2013)
Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression
Suqin He et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2013)
Immunogenicity assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine
Montserrat Carrasco-Triguero et al.
BIOANALYSIS (2013)
Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non-Small Cell Lung Cancer
Takeshi Shimamura et al.
CLINICAL CANCER RESEARCH (2012)
Discovery of Aryloxy Tetramethylcyclobutanes as Novel Androgen Receptor Antagonists
Chuangxing Guo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Novel Synthesis and Biological Evaluation of Enigmols as Therapeutic Agents for Treating Prostate Cancer
Ethel C. Garnier-Amblard et al.
ACS MEDICINAL CHEMISTRY LETTERS (2011)
Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
Rong Hu et al.
CANCER RESEARCH (2009)
Anti-metastatic effects of liposomal gemcitabine in a human orthotopic LNCaP prostate cancer xenograft model
Peter Jantscheff et al.
CLINICAL & EXPERIMENTAL METASTASIS (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Extracellular HSP90: Conquering the cell surface
Katerina Sidera et al.
CELL CYCLE (2008)
A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion
S. Tsutsumi et al.
ONCOGENE (2008)
A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2
Katerina Sidera et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity
KP De Jesus-Tran et al.
PROTEIN SCIENCE (2006)
Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases
B Becker et al.
EXPERIMENTAL DERMATOLOGY (2004)
Involvement of cell surface HSP90 in cell migration reveals a novel role in the developing nervous system
K Sidera et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Functional proteomic screens reveal an essential extracellular role for hsp90α in cancer cell invasiveness
BK Eustace et al.
NATURE CELL BIOLOGY (2004)
分享论文
